• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A new reality of molecular surveillance for resected lung cancer.

作者信息

Shi Shuo, Christopoulos Petros

机构信息

Department of Medical Oncology, Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg Germany.

Department of Translational Pulmonology, Heidelberg University Hospital, Heidelberg, Germany.

出版信息

Transl Lung Cancer Res. 2025 Jul 31;14(7):2369-2373. doi: 10.21037/tlcr-2025-523. Epub 2025 Jul 17.

DOI:10.21037/tlcr-2025-523
PMID:40799451
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12337028/
Abstract
摘要

相似文献

1
A new reality of molecular surveillance for resected lung cancer.切除性肺癌分子监测的新现状
Transl Lung Cancer Res. 2025 Jul 31;14(7):2369-2373. doi: 10.21037/tlcr-2025-523. Epub 2025 Jul 17.
2
Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.循环肿瘤 DNA 分析检测肺癌微小残留病灶的准确性：一项荟萃分析。
BMC Med. 2023 May 12;21(1):180. doi: 10.1186/s12916-023-02849-z.
3
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.液体活检能否通过低深度全基因组测序检测肉瘤患者的循环肿瘤DNA？一项初步评估。
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
4
Recent advances in liquid biopsy for precision oncology: emerging biomarkers and clinical applications in lung cancer.精准肿瘤学液体活检的最新进展：肺癌中新兴的生物标志物及临床应用
Future Oncol. 2025 Aug 5:1-19. doi: 10.1080/14796694.2025.2542051.
5
Clinical Utility of ctDNA Analysis in Lung Cancer-A Review.循环肿瘤DNA分析在肺癌中的临床应用——综述
Adv Respir Med. 2025 Jun 12;93(3):17. doi: 10.3390/arm93030017.
6
Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.针对接受根治性治疗的非小细胞肺癌患者，采用个体化、肿瘤相关的循环肿瘤 DNA 检测方法进行微小残留病灶检测。
Thorac Cancer. 2024 May;15(13):1095-1102. doi: 10.1111/1759-7714.15281. Epub 2024 Apr 1.
7
Utility of circulating tumor DNA to detect minimal residual disease in colorectal cancer: A systematic review and network meta-analysis.循环肿瘤DNA检测结直肠癌微小残留病的效用：一项系统评价和网状Meta分析
Int J Cancer. 2025 Aug 15;157(4):722-740. doi: 10.1002/ijc.35442. Epub 2025 Apr 28.
8
Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.循环肿瘤 DNA 作为结直肠癌根治性切除术患者（接受或不接受辅助化疗）微小残留病评估和复发风险的标志物：一项系统评价和荟萃分析。
Int J Mol Sci. 2023 Jun 16;24(12):10230. doi: 10.3390/ijms241210230.
9
Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer.对I-III期结肠癌切除患者进行ctDNA的真实世界监测可可靠预测癌症复发和治疗效果。
Ann Surg. 2025 Aug 7. doi: 10.1097/SLA.0000000000006887.
10
Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma.通过循环肿瘤DNA评估大B细胞淋巴瘤的缓解情况
J Clin Oncol. 2025 Aug 13:101200JCO2501534. doi: 10.1200/JCO-25-01534.

本文引用的文献

1
Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer.随访分析增强了对局限性非小细胞肺癌分子残留病的理解。
Clin Cancer Res. 2025 Apr 1;31(7):1305-1314. doi: 10.1158/1078-0432.CCR-24-2909.
2
The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.非小细胞肺癌围手术期治疗的新兴模式：一项叙述性综述
Chin Clin Oncol. 2024 Feb;13(1):12. doi: 10.21037/cco-23-137. Epub 2024 Feb 5.
3
Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non-Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201).
根治性切除术后基于纵向不可检测分子残留疾病的 IB 期至 IIIA 期非小细胞肺癌患者无辅助治疗策略：前瞻性、多中心、单臂研究（CTONG 2201）。
Clin Lung Cancer. 2024 Jan;25(1):e1-e4. doi: 10.1016/j.cllc.2023.09.008. Epub 2023 Oct 6.
4
Early Detection of Lung Cancer Using Small RNAs.利用小 RNA 进行肺癌的早期检测。
J Thorac Oncol. 2023 Nov;18(11):1504-1523. doi: 10.1016/j.jtho.2023.07.005. Epub 2023 Jul 16.
5
Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients.ALK 阳性非小细胞肺癌患者循环游离 DNA 甲基化的纵向监测。
Clin Epigenetics. 2022 Dec 2;14(1):163. doi: 10.1186/s13148-022-01387-4.
6
Liquid biopsies come of age in lung cancer.液体活检在肺癌领域已走向成熟。
Transl Lung Cancer Res. 2022 May;11(5):706-710. doi: 10.21037/tlcr-22-268.
7
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer.纵向不可检测的分子残留疾病定义了局限性非小细胞肺癌中的潜在治愈人群。
Cancer Discov. 2022 Jul 6;12(7):1690-1701. doi: 10.1158/2159-8290.CD-21-1486.
8
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.新辅助纳武利尤单抗联合化疗治疗可切除肺癌。
N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11.
9
Antibody drug conjugate: the "biological missile" for targeted cancer therapy.抗体药物偶联物：靶向癌症治疗的“生物导弹”。
Signal Transduct Target Ther. 2022 Mar 22;7(1):93. doi: 10.1038/s41392-022-00947-7.
10
Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis.使用循环肿瘤DNA分析早期识别ALK重排肺癌的疾病进展
NPJ Precis Oncol. 2021 Dec 7;5(1):100. doi: 10.1038/s41698-021-00239-3.